Phase 1Active, not recruiting
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease
- Sponsor
- ProMis Neurosciences, Inc (Industry)
- Enrolment
- 144 enrolled
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- PMN310; Placebo
- Ages
- adults, older adults
- Registry
- NCT06750432
From the registry
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Primary outcomes
- Safety and tolerability of PMN310 following repeat intravenous infusions of PMN310
- Biomarker response to PMN310 following repeat intravenous infusions of PMN310